Lon S. Schneider on Donanemab Approval Likely to Pose New Quandaries for Clinicians
COMMENT The Perfect Meeting Three years ago, an FDA adviser called the agency’s approval of Aduhelm “probably the worst drug approval decision in recent U.S. history.” By contrast, a current adviser called today’s donanemab session “a perfect meeting.” FDA got th